Changes in leukocyte gene expression profiles induced by antineoplastic chemotherapy

González-Fernández,Rebeca; Morales,Manuel; Avila,Julio; Martín-Vasallo,Pablo

doi:10.3892/ol.2012.669

Changes in leukocyte gene expression profiles induced by antineoplastic chemotherapy

Authors:
- Rebeca González-Fernández
- Manuel Morales
- Julio Avila
- Pablo Martín-Vasallo
View Affiliations

Affiliations: Laboratory of Developmental Biology, Department of Biochemistry and Molecular Biology, University of La Laguna, La Laguna 38201, Tenerife, Spain, Service of Medical Oncology, Hospital Universitario Ntra Sra de Candelaria, Santa Cruz de Tenerife 38010, Tenerife, Spain
Published online on: April 3, 2012 https://doi.org/10.3892/ol.2012.669
Pages: 1341-1349

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we studied changes in gene expression induced by chemotherapy (CT) on normal peripheral blood leukocytes (PBLs), at baseline and following three CT cycles, in order to identify which genes were specifically affected and were potentially useful as biomarkers for a personalised prognosis and follow-up. A PBL subtraction cDNA library was constructed from four patients undergoing CT with paclitaxel and carboplatin (PC). mRNA from the PBLs was isolated prior to the patients receiving the first cycle and following the completion of the third cycle. The library was screened and the expression of the identified genes was studied in PBLs obtained from patients suffering from cancer prior to and following three cycles of PC and a reference group of patients undergoing treatment with Adriamycin-cyclophosphamide (AC). From the 1,200 screened colonies, 65 positive clones showed varied expression intensity and were sequenced; 27 of these were mitochondrial DNA and 38 clones (27 different) were coded for cytosolic and nuclear proteins. The genes that were studied in patients undergoing CT were ATM (ataxia-telangiectasia mutated gene), eIF4B (translation initiation factor 4B), MATR3 (Matrin 3), MORC3 (microrchidia 3), PCMTD2 (protein-L-isoaspartate O-methyltransferase), PDCD10 (programmed cell death gene 10), PSMB1 (proteasome subunit type β), RMND5A (required for meiotic nuclear division 5 homologue A), RUNX2 (runt-related transcription factor 2), SACM1L (suppressor of actin mutations 1-like), TMEM66 (transmembrane protein 66) and ZNF644 (zinc finger protein 644). Certain variations were observed in the expression of the genes that are involved in drug resistance mechanisms, some of which may be secondary to non-desirable effects and others of which may cause the undesired effects of CT. The expression of genes with a dynamic cellular role showed a marked positive correlation, indicating that their upregulation may be involved in a specific pattern of cell survival versus apoptosis in response to the cell damage induced by CT. Whether these CT-induced changes are random or directed in a specific selection-evolution manner needs to be elucidated.

View Figures

View References

1	DeVita V; DePinho RA, Lawrence TS, Rosenberg SA and Weinberg RA: DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th edition. Lippincott Williams & Wilkins; Philadelphia: 2011
2	Perry MC: The Chemotherapy Source Book. 4th edition. Lippincott Williams & Wilkins; Philadelphia: 2008
3	Kavallaris M, Kuo DY, Burkhart CA, et al: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 100:1282–1293. 1997. View Article : Google Scholar : PubMed/NCBI
4	Steffensen KD, Waldstrom M and Jakobsen A: The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer. 19:820–825. 2009. View Article : Google Scholar : PubMed/NCBI
5	Smith L, Watson MB, O’Kane SL, Drew PJ, Lind MJ and Cawkwell L: The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther. 5:2115–2120. 2006. View Article : Google Scholar : PubMed/NCBI
6	Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW and Salmon SE: cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther. 299:434–441. 2001.
7	Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH and Huitema AD: Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics. 18:515–523. 2008. View Article : Google Scholar
8	Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning: A Laboratory Manual. 2nd edition. Cold Spring Harbor Laboratory; 1989
9	Altschul SF, Madden TL, Schaffer AA, et al: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389–3402. 1997. View Article : Google Scholar : PubMed/NCBI
10	Velculescu VE, Zhang L, Vogelstein B and Kinzler KW: Serial analysis of gene expression. Science. 270:484–487. 1995. View Article : Google Scholar : PubMed/NCBI
11	Liang P and Pardee AB: Differential display of mRNA by PCR. Curr Protoc Mol Biol. Chapter 25(Unit 25): pp. B32001
12	Diatchenko L, Lau YF, Campbell AP, et al: Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA. 93:6025–6030. 1996. View Article : Google Scholar
13	Bensimon A, Aebersold R and Shiloh Y: Beyond ATM: the protein kinase landscape of the DNA damage response. FEBS Lett. 585:1625–1639. 2011. View Article : Google Scholar : PubMed/NCBI
14	Lavin MF: Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. 9:759–769. 2008. View Article : Google Scholar : PubMed/NCBI
15	Parsyan A, Svitkin Y, Shahbazian D, et al: mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol. 12:235–245. 2011. View Article : Google Scholar : PubMed/NCBI
16	Przygodzka P, Boncela J and Cierniewski CS: Matrin 3 as a key regulator of endothelial cell survival. Exp Cell Res. 317:802–811. 2011. View Article : Google Scholar : PubMed/NCBI
17	Valencia CA, Ju W and Liu R: Matrin 3 is a Ca²⁺/calmodulin-binding protein cleaved by caspases. Biochem Biophys Res Commun. 361:281–286. 2007.PubMed/NCBI
18	Kula A, Guerra J, Knezevich A, Kleva D, Myers MP and Marcello A: Characterization of the HIV-1 RNA associated proteome identifies Matrin 3 as a nuclear cofactor of Rev function. Retrovirology. 8:602011. View Article : Google Scholar : PubMed/NCBI
19	Takahashi K, Yoshida N, Murakami N, et al: Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell. 18:1701–1709. 2007. View Article : Google Scholar : PubMed/NCBI
20	Shimizu T, Matsuoka Y and Shirasawa T: Biological significance of isoaspartate and its repair system. Biol Pharm Bull. 28:1590–1596. 2005. View Article : Google Scholar : PubMed/NCBI
21	Young GW, Hoofring SA, Mamula MJ, et al: Protein L-isoaspartyl methyltransferase catalyzes in vivo racemization of Aspartate-25 in mammalian histone H2B. J Biol Chem. 280:26094–26098. 2005. View Article : Google Scholar : PubMed/NCBI
22	Carter WG and Aswad DW: Formation, localization, and repair of L-isoaspartyl sites in histones H2A and H2B in nucleosomes from rat liver and chicken erythrocytes. Biochemistry. 47:10757–10764. 2008. View Article : Google Scholar : PubMed/NCBI
23	Lauenborg B, Kopp K, Krejsgaard T, et al: Programmed cell death-10 enhances proliferation and protects malignant T cells from apoptosis. APMIS. 118:719–728. 2010. View Article : Google Scholar : PubMed/NCBI
24	Ma X, Zhao H, Shan J, et al: PDCD10 interacts with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway. Mol Biol Cell. 18:1965–1978. 2007. View Article : Google Scholar : PubMed/NCBI
25	Aguirre AJ, Brennan C, Bailey G, et al: High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci USA. 101:9067–9072. 2004. View Article : Google Scholar : PubMed/NCBI
26	Huerta S, Harris DM, Jazirehi A, et al: Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol. 22:663–670. 2003.PubMed/NCBI
27	Keutgens A, Zhang X, Shostak K, et al: BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1. J Biol Chem. 285:25831–25840. 2010. View Article : Google Scholar : PubMed/NCBI
28	Kobayashi N, Yang J, Ueda A, et al: RanBPM, Muskelin, p48EMLP, p44CTLH, and the armadillo-repeat proteins ARMC8alpha and ARMC8beta are components of the CTLH complex. Gene. 396:236–247. 2007. View Article : Google Scholar : PubMed/NCBI
29	Pratap J, Lian JB, Javed A, et al: Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev. 25:589–600. 2006. View Article : Google Scholar : PubMed/NCBI
30	Eliseev RA, Dong YF, Sampson E, et al: Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis. Oncogene. 27:3605–3614. 2008. View Article : Google Scholar : PubMed/NCBI
31	Rohde HM, Cheong FY, Konrad G, Paiha K, Mayinger P and Boehmelt G: The human phosphatidylinositol phosphatase SAC1 interacts with the coatomer I complex. J Biol Chem. 278:52689–52699. 2003. View Article : Google Scholar : PubMed/NCBI
32	Liu Y, Boukhelifa M, Tribble E, et al: The Sac1 phosphoinositide phosphatase regulates Golgi membrane morphology and mitotic spindle organization in mammals. Mol Biol Cell. 19:3080–3096. 2008. View Article : Google Scholar : PubMed/NCBI
33	Blagoveshchenskaya A, Cheong FY, Rohde HM, et al: Integration of Golgi trafficking and growth factor signaling by the lipid phosphatase SAC1. J Cell Biol. 180:803–812. 2008. View Article : Google Scholar : PubMed/NCBI
34	Mori T, Nishimura N, Hasegawa D, et al: Persistent detection of a novel MLL-SACM1L rearrangement in the absence of leukemia. Leuk Res. 34:1398–1401. 2010. View Article : Google Scholar : PubMed/NCBI
35	Romanuik TL, Ueda T, Le N, et al: Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol. 175:2264–2276. 2009. View Article : Google Scholar : PubMed/NCBI
36	Romanuik TL, Wang G, Holt RA, Jones SJ, Marra MA and Sadar MD: Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries. BMC Genomics. 10:4762009. View Article : Google Scholar : PubMed/NCBI
37	Mannherz O, Mertens D, Hahn M and Lichter P: Functional screening for proapoptotic genes by reverse transfection cell array technology. Genomics. 87:665–672. 2006. View Article : Google Scholar : PubMed/NCBI
38	Mulligan P, Westbrook TF, Ottinger M, et al: CDYL bridges REST and histone methyltransferases for gene repression and supp-ression of cellular transformation. Mol Cell. 32:718–726. 2008. View Article : Google Scholar : PubMed/NCBI
39	Matsumoto K, Ishii N, Yoshida S, Shiosaka S, Wanaka A and Tohyama M: Molecular cloning and distinct developmental expression pattern of spliced forms of a novel zinc finger gene wiz in the mouse cerebellum. Brain Res Mol Brain Res. 61:179–189. 1998. View Article : Google Scholar : PubMed/NCBI